Does Medicaid cover Ozempic?

If you’ve been prescribed one of the popular GLP-1 medications—Wegovy, Ozempic, or Mounjaro—you’re probably wondering: will my insurance actually cover this? These groundbreaking medications can be life-changing for weight loss and diabetes management, but their high price tags (often over $1,000 per month) make insurance coverage critical for most people.

The short answer? It depends—on your insurance type, your diagnosis, and your state. Coverage for GLP-1 medications is one of the most complicated and rapidly changing areas of health insurance in 2025. While diabetes use is generally covered, weight-loss coverage remains a patchwork of approvals, denials, and shifting policies.

In this comprehensive guide, we’ll break down exactly what’s covered (and what’s not), how to navigate prior authorization, what to do if you’re denied, and how to access these medications affordably—even without insurance. Whether you have commercial insurance, Medicare, or Medicaid, or you’re considering cash-pay options, we’ll help you understand your choices.

Understanding GLP-1 Medications: What They Are and Who Needs Them

Before diving into insurance specifics, let’s clarify what these medications do and why coverage matters.

GLP-1 receptor agonists are a class of injectable medications that mimic a natural hormone (glucagon-like peptide-1) to regulate blood sugar and appetite. They’ve revolutionized treatment for both Type 2 diabetes and obesity:

• Ozempic (semaglutide): FDA-approved for Type 2 diabetes; reduces blood sugar and cardiovascular risk
• Wegovy (semaglutide): Same active ingredient as Ozempic but FDA-approved specifically for chronic weight management in adults with obesity or overweight with related health conditions
• Mounjaro (tirzepatide): FDA-approved for Type 2 diabetes; works on two hormone pathways (GLP-1 and GIP) for even greater effect

The challenge? These medications are expensive brand-name drugs with no generic alternatives. Without insurance or savings programs, you’re looking at $900–$1,350 per month—making coverage decisions critically important for long-term treatment.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance Coverage: What to Expect

Coverage for Diabetes (Ozempic and Mounjaro)

If you have Type 2 diabetes and a commercial health plan, there’s good news: insurers generally cover Ozempic and Mounjaro as essential diabetes medications. However, coverage usually comes with requirements:

Typical coverage criteria for diabetes use:

• Confirmed Type 2 diabetes diagnosis (A1c levels documented)
• Prior trial of first-line medications (usually metformin) unless contraindicated
• Prior authorization to verify appropriate use
• Placement on Tier 3 (non-preferred brand) or Tier 4 (specialty), meaning higher copays or coinsurance

Most commercial plans treat these medications similarly to insulin or other advanced diabetes drugs. Your doctor will need to submit clinical documentation showing that standard treatments haven’t adequately controlled your blood sugar or that you have cardiovascular risk factors warranting GLP-1 therapy.

Important limitation: Insurance will not cover Ozempic or Mounjaro prescribed off-label for weight loss alone. If you don’t have diabetes, insurers will deny these prescriptions and direct you to Wegovy (the FDA-approved weight-loss formulation)—if they cover weight-loss medications at all.

Coverage for Weight Loss (Wegovy)

This is where insurance coverage becomes far more restrictive and unpredictable.

The reality: Many employer health plans and commercial insurers either exclude obesity medications entirely or impose stringent criteria that make approval difficult. Weight-loss drugs are considered ‘optional benefits,’ and with Wegovy’s high cost (over $1,300/month list price), many employers opt out of coverage to control costs.

If your plan does cover Wegovy, expect these requirements:

1. BMI threshold: Usually ≥30 kg/m² (obesity), or ≥27 kg/m² with at least one weight-related comorbidity (hypertension, Type 2 diabetes, high cholesterol, sleep apnea)
2. Documented lifestyle intervention: Proof of at least 6 months of supervised diet and exercise program without adequate weight loss
3. Medical necessity: Documentation of obesity-related health risks
4. Step therapy: Some plans require trying older, cheaper weight-loss medications first (such as phentermine or Saxenda)
5. Ongoing monitoring: Reauthorization every 3–6 months, contingent on achieving weight-loss goals (typically ≥5% body weight reduction)

Major insurers like Aetna, Cigna, and UnitedHealthcare have implemented these strict prior authorization protocols. For example, Aetna’s policy (updated May 2024) requires patients to be age 18+, meet BMI criteria, complete a structured weight management program, and demonstrate inadequate response to lifestyle modification before approving Wegovy.

Even with approval, you’ll likely face high out-of-pocket costs. Wegovy is typically placed on specialty tiers with 20–40% coinsurance rather than flat copays, meaning you could still pay $200–$500 monthly even with insurance coverage.

Common Denial Reasons and How to Avoid Them

Understanding why claims get denied can help you prepare a stronger prior authorization request:

Top reasons for denial:

1. BMI doesn’t meet threshold – Ensure your provider documents current, accurate measurements
2. Insufficient documentation of lifestyle efforts – Keep records of weight-loss programs, nutritionist visits, exercise plans
3. Missing comorbidity documentation – If your BMI is 27–29.9, you must have documented weight-related conditions
4. Off-label use – Using Ozempic for weight loss when you don’t have diabetes will be denied
5. Plan exclusion – Some policies explicitly exclude all ‘weight control’ drugs regardless of medical necessity

Pro tip: Before your doctor submits prior authorization, review your plan’s medical policy for GLP-1 medications (usually available on your insurance website or by calling member services). Make sure all required documentation is included upfront to avoid unnecessary delays.

Medicare Coverage: Limited Options

Medicare Part D and Weight-Loss Medications

Here’s the frustrating truth: Traditional Medicare Part D does not cover medications prescribed solely for weight loss. This is mandated by federal law—the Social Security Act specifically allows Medicare to exclude ‘drugs used for weight loss.’

This means if you’re on original Medicare:

• Wegovy is NOT covered for obesity treatment
• Ozempic and Mounjaro are covered when prescribed for Type 2 diabetes
• Coverage for diabetes use follows standard Part D formulary rules (prior authorization, tier placement, step therapy)

The Important Exception: Cardiovascular Indication

There’s one significant exception that expanded in 2024: Medicare will cover Wegovy when prescribed specifically for reducing cardiovascular risk in obese patients with established heart disease. This followed FDA approval for this indication in March 2024.

To qualify for this coverage:

• You must have documented cardiovascular disease (history of heart attack, stroke, peripheral artery disease)
• AND obesity (BMI ≥27 typically)
• Prescription must be written specifically for CV risk reduction, not weight loss

This creates a narrow pathway for some Medicare beneficiaries to access Wegovy, though it remains unavailable for the broader obesity population on Medicare.

Medicare Advantage Plans

Some Medicare Advantage (Part C) plans began offering limited obesity medication coverage in 2025 as a supplemental benefit. However, this varies dramatically by plan and region. If you’re considering Medicare Advantage during open enrollment, specifically ask about weight-management medication coverage—it’s not standard.

Medicaid Coverage: State-by-State Variation

Medicaid coverage for GLP-1 weight-loss medications is perhaps the most fragmented and rapidly changing landscape.

The Federal Rule

Federal Medicaid law gives states the option to exclude ‘drugs used for weight loss’ from coverage. Most states have historically exercised this option due to budget concerns. However, as of 2024, approximately 13 states chose to cover obesity medications under their Medicaid programs—though this number is now declining as states face fiscal pressures.

State-by-State Breakdown (Priority States)

California (Medi-Cal):

• Current status through 12/31/2025: Covered with prior authorization
• Effective 1/1/2026: Coverage ENDS for adults
• During 2025, strict PA required: BMI ≥30 (or ≥27 + comorbidity), 6-month supervised diet documented, quantity limits (4 pens/28 days)
• Pediatric patients (<21) may still access via EPSDT even after adult coverage ends
• Why the change? Budget cuts to control rising Medicaid pharmacy spending

Texas Medicaid:

• Status: NOT covered for adults age 21+
• Texas explicitly excludes all obesity medications (Wegovy, Saxenda, etc.) from its formulary
• Only available to children/adolescents through case-by-case exception requests
• Ozempic/Mounjaro covered only for documented Type 2 diabetes

Florida Medicaid:

• Status: NOT covered
• State utilizes the federal exclusion for weight-loss drugs
• No GLP-1 medications available for obesity treatment regardless of medical necessity
• Diabetes-indicated GLP-1s (Ozempic, Mounjaro) covered only for T2D diagnosis

New York (NYRx):

• Status: COVERED with strict prior authorization
• One of the most comprehensive state Medicaid programs for obesity treatment
• Criteria: BMI ≥30 or ≥27 + comorbidity, documented lifestyle modification, age ≥18
• Quantity limits and periodic reauthorization required
• Continues coverage as of 2025 (unlike states cutting programs)

Pennsylvania Medicaid:

• Status through 2025: Covered with extensive PA criteria
• Effective January 2026: Coverage ENDING
• 2025 requirements: BMI ≥30 (or ≥27 + ≥1 comorbidity), documented weight-related condition, prior diet/exercise attempts
• Special rule: Diabetic patients must try preferred diabetes GLP-1s first before Wegovy approval
• Dual-eligible patients (Medicare + Medicaid) could get Wegovy through PA Medicaid since Medicare won’t cover

Illinois Medicaid (HFS):

• Status: NOT covered
• Despite state employee plans adding obesity drug coverage in 2023, Medicaid program has not adopted coverage
• No pathway for Wegovy, Saxenda, or other anti-obesity medications

Key Medicaid Trends

The trend is concerning: Multiple states are eliminating obesity drug coverage in 2025–2026 due to exploding costs. California and Pennsylvania—two states that pioneered Medicaid coverage—are both ending programs January 1, 2026. States cite budget impacts exceeding projections, with some spending over $100 million annually on GLP-1s.

If you have Medicaid coverage for these medications now, confirm your state’s 2026 policy—and explore alternatives before losing access.

Navigating Prior Authorization: A Step-by-Step Guide

Whether you have commercial insurance, Medicare, or Medicaid, prior authorization is almost inevitable for GLP-1 medications. Here’s how to navigate the process:

Before Submitting

1. Verify your plan’s requirements – Call member services or check your formulary online for specific criteria
2. Gather documentation:

• Recent office notes with BMI calculations
• Weight history over past 6–12 months
• Records of supervised diet/exercise programs
• Lab results (A1c if diabetic, lipids, blood pressure readings)
• Documentation of obesity-related comorbidities

1. Consider timing – Submit early in your treatment plan; some insurers require 2–4 weeks for review

What Your Doctor Needs to Submit

Your healthcare provider (or their office staff) will submit the prior authorization, typically including:

• Completed PA form specific to your insurer
• Letter of medical necessity explaining clinical rationale
• Supporting clinical documentation (office notes, labs, weight logs)
• Proof of prior treatments attempted (diet program attendance, previous medications)
• ICD-10 diagnosis codes (E66.01 for morbid obesity, E11 for Type 2 diabetes, etc.)

Tip: Telehealth providers like Klarity Health often handle prior authorizations as part of their service, removing administrative burden from patients while ensuring comprehensive documentation.

Expected Timeline

• Standard review: 5–7 business days for initial decision
• Expedited review: 24–72 hours (available if medically urgent)
• Appeal process: 30–60 days for internal appeal review

During review, insurers may request additional information—respond promptly to avoid automatic denials.

If You’re Denied

Don’t give up. A significant percentage of initial PA denials are overturned on appeal when proper documentation is provided.

Appeal steps:

1. Request written denial explanation – Understand the specific reason
2. Review denial against plan’s medical policy – Identify gaps in documentation
3. Gather additional evidence:

• More detailed provider letter addressing denial reasons
• Published clinical guidelines supporting use
• Documentation of any missing criteria

1. Submit formal appeal within timeframe specified (usually 180 days)
2. Consider external review if internal appeal fails (state insurance departments offer independent reviews)

For denials based on plan exclusions (not medical necessity), appeals rarely succeed unless you can argue an alternative covered indication. In these cases, exploring self-pay options may be more practical.

Affordable Access Without Insurance: Self-Pay Options That Actually Work

If insurance doesn’t cover your medication—or you’re uninsured—don’t assume GLP-1 medications are out of reach. Pricing has changed dramatically in late 2025, with new programs making these drugs far more accessible.

Manufacturer Savings Programs (2025 Updates)

Novo Nordisk (Wegovy and Ozempic):

For insured patients:

• Savings card: Reduces copay to as low as $0–$25 per month (maximum savings $225/month)
• Available for commercial insurance holders (cannot be used with government insurance)
• Covers up to 24 months of treatment

For cash-pay patients:

• Wegovy Access program: $349/month (down from previous $499)
• NovoCare self-pay: Same pricing through participating pharmacies
• GoodRx partnership (November 2025):
• $199/month for first 2 fills, then $349/month ongoing
• Applies to both Wegovy and Ozempic
• Available at nearly all major pharmacies nationwide

Patient assistance for low-income uninsured:

• Novo Nordisk Patient Assistance Program provides free medication for those meeting income criteria (typically <400% federal poverty level)
• Application through healthcare provider or NovoCare

Eli Lilly (Mounjaro and Zepbound):

For insured patients with diabetes:

• Mounjaro Savings Card: $25/month for up to 12 fills
• Requires commercial insurance and Type 2 diabetes diagnosis
• Maximum savings up to ~$500/month

For cash-pay patients:

• Zepbound single-dose vials (December 2025):
• 2.5 mg: $399/month (down from $549)
• 5 mg: $549/month (down from $649)
• 7.5–15 mg: $649–$999/month
• Available through LillyDirect (mail-order) and select pharmacies

Patient assistance:

• Lilly Cares Foundation provides free medication for eligible uninsured patients
• Income-based qualification

GoodRx and Discount Programs

The November 2025 GoodRx-Novo Nordisk partnership represents the most significant pricing breakthrough:

GoodRx Weight Loss Program:

• $39/month telemedicine subscription (includes virtual doctor visits and treatment plan)
• Medication pricing: $199/month introductory (first 2 months), then $349/month
• Covers Wegovy and Ozempic (for weight loss use)
• No insurance required; available to all cash-pay patients
• Total first-month cost: ~$238 (subscription + medication), then ~$388/month ongoing

This is 60–70% less than list price and makes these medications accessible to millions who previously couldn’t afford them.

Other discount card options:

• SingleCare: Ozempic ~$800–$900/month with coupon
• RxSaver: Similar discounts, varies by pharmacy
• Always compare multiple platforms—prices can differ by $100+ between pharmacies

Generic Alternatives and Compounded Options

Important clarification: There are no FDA-approved generic versions of Wegovy, Ozempic, or Mounjaro. Patents extend into the 2030s.

However, some pharmacies offer compounded semaglutide or tirzepatide at lower prices ($200–$400/month). These are custom-mixed formulations, not approved by the FDA.

Risks of compounded GLP-1s:

• No FDA oversight for quality or consistency
• Dosing accuracy not guaranteed
• Unknown long-term safety
• May not have same effectiveness as brand-name drugs

The FDA and manufacturers have issued warnings about compounded versions. While they may be cheaper, they carry risks that should be carefully weighed with your healthcare provider.

Legitimate older alternatives (FDA-approved):

• Saxenda (liraglutide): Daily injection for weight loss, ~$1,400/month (similar cost issues)
• Phentermine: Older oral weight-loss med, $30–$100/month, short-term use only
• Orlistat (Alli): Over-the-counter, ~$50/month, modest effectiveness

How Klarity Health Can Help

If you’re navigating complex insurance coverage or exploring self-pay options, Klarity Health offers a streamlined path to GLP-1 treatment:

• Transparent telemedicine pricing: Know upfront what your visit costs—no surprise bills
• Accept both insurance and cash pay: Submit to your insurance if covered, or access affordable cash-pay options
• Provider availability: Connect with licensed providers who can prescribe and manage GLP-1 medications via secure video visits
• Prior authorization support: Providers handle insurance paperwork and appeals when needed
• Medication access: Get prescriptions sent to your pharmacy of choice, with guidance on savings programs

Rather than navigating multiple systems alone, Klarity Health consolidates care—making it easier to access evidence-based weight management and diabetes treatment regardless of your insurance situation.

Telehealth and Insurance Coverage: What You Need to Know

Good news for remote care: Telehealth visits for weight management and medication prescribing are widely covered by insurance in 2025.

Insurance Coverage for Telehealth

Commercial insurance:

• Over 40 states have telehealth parity laws requiring insurers to cover virtual visits the same as in-person care
• If your plan covers obesity or diabetes consultations, it will cover them via telemedicine
• Copays are typically identical to office visit copays

Medicare:

• Pandemic-era telehealth expansions largely remain in place through 2025
• Medicare covers telehealth for diabetes management and certain preventive services
• Weight-management counseling (covered as preventive care under certain circumstances) can be delivered virtually

Medicaid:

• State-dependent, but most states expanded telehealth access permanently
• Check your state Medicaid program for specific telehealth policies

What to Confirm Before Your Visit

When using telehealth platforms for GLP-1 prescriptions:

1. Is the provider in-network? Out-of-network telehealth may not be covered or may have higher costs
2. Does your plan require live video? Some insurers don’t cover phone-only or text consultations
3. Will prescriptions be covered? The telehealth visit may be covered while the medication itself requires separate PA
4. What’s included in platform fees? Some telehealth services charge separate visit fees even if you have insurance (confirm whether they bill your insurance or require cash payment)

Platforms like Klarity Health accept insurance when applicable and clearly outline cash-pay costs when insurance doesn’t cover services—eliminating billing surprises.

Medication Coverage Comparison Table

To help you quickly understand coverage differences, here’s a comprehensive comparison:

All three medications are brand-only (no generics available as of 2025).

State Medicaid Coverage Quick Reference

Frequently Asked Questions About GLP-1 Insurance Coverage

Will my insurance cover Ozempic for weight loss if I don’t have diabetes?

No. Insurance companies strictly enforce FDA labeling—Ozempic is approved only for Type 2 diabetes. If you’re seeking weight-loss treatment without diabetes, insurers will deny Ozempic and require you to try Wegovy (if your plan covers obesity medications at all). Using Ozempic off-label for weight loss will result in claim denials.

How long does prior authorization take?

Standard prior authorizations typically take 5–7 business days for initial review. Your provider can request expedited review (24–72 hours) if medically necessary. If the insurer requests additional information, expect another week. Start the PA process early—don’t wait until you’ve run out of medication.

Can I appeal if my insurance denies coverage?

Absolutely. Most PA denials can be appealed, and many are overturned when proper documentation is submitted. You typically have 180 days to file an internal appeal. If that fails, request an external review through your state insurance department. Success rates vary, but appeals based on missing documentation (rather than plan exclusions) have reasonable approval rates.

Does Medicare cover any GLP-1 medications for weight loss?

Standard Medicare Part D does not cover medications prescribed solely for weight loss—it’s prohibited by federal law. However, Medicare does cover Wegovy when prescribed specifically for cardiovascular risk reduction in obese patients with heart disease (not for weight loss itself). If you have diabetes, Medicare covers Ozempic and Mounjaro as diabetes medications.

What’s the cheapest way to get these medications without insurance?

As of late 2025, the GoodRx Weight Loss program offers the best pricing: $199/month for your first two fills, then $349/month ongoing for Wegovy or Ozempic. This represents 60–70% savings versus list price. Additionally, check manufacturer patient assistance programs if you’re uninsured and meet income qualifications—you may qualify for free medication.

Will my insurance cover telehealth visits for weight-loss medication management?

Most likely, yes. Commercial insurance, Medicare, and Medicaid all expanded telehealth coverage, and over 40 states have parity laws requiring equal coverage of virtual and in-person visits. Confirm your plan covers weight management or obesity counseling, and ensure the telehealth provider is in-network. Copays typically match office visit copays.

Are compounded semaglutide or tirzepatide covered by insurance?

No. Insurance will not cover compounded versions of these medications—only FDA-approved brand-name drugs (Wegovy, Ozempic, Mounjaro, Zepbound). Compounded versions are not FDA-approved and carry quality/safety risks. If cost is a concern, explore manufacturer savings programs rather than compounded alternatives.

What happens if my state Medicaid stops covering obesity medications?

If you currently receive Wegovy through Medicaid in a state ending coverage (like California or Pennsylvania in 2026), you’ll need to transition to alternative options:

• Explore manufacturer patient assistance programs (income-based free medication)
• Switch to self-pay with savings programs ($349/month via GoodRx/NovoCare)
• Consider older, cheaper weight-loss medications your doctor recommends
• If you have comorbid conditions, work with your provider on alternative covered treatments

Talk to your provider before your coverage ends to develop a transition plan.

Taking Your Next Steps

Navigating GLP-1 insurance coverage is complex, but understanding your options empowers you to access these life-changing medications—whether through insurance or affordable self-pay programs.

If you have insurance: Contact your plan to understand specific coverage policies, then work closely with your provider to submit a thorough prior authorization with all required documentation.

If you’re uninsured or denied: Don’t abandon treatment. New manufacturer programs and partnerships have made these medications more accessible than ever, with self-pay options now under $350/month in many cases.

If you’re considering telehealth: Platforms like Klarity Health offer a streamlined path to GLP-1 prescriptions with transparent pricing, insurance billing support, and provider availability—making it easier to start or continue treatment regardless of your coverage situation.

Whether you’re managing Type 2 diabetes or pursuing sustainable weight loss, access to evidence-based GLP-1 therapy shouldn’t be determined solely by insurance complexity. With the right information and resources, you can find a path to the care you need.

Ready to explore your options? Klarity Health connects you with licensed providers who can evaluate your candidacy for GLP-1 medications, handle insurance complexities, and help you access affordable treatment—all through convenient telehealth visits that fit your schedule.

Research Currency Statement

Verified coverage status and pricing are accurate as of December 17, 2025. Always check your own insurance formulary for the latest details, as policies can change with new plan years.

Top Citations:

1. Aetna Clinical Policy – Weight Loss GLP-1 Agonists (May 2024) – Official insurer prior authorization criteria detailing BMI requirements, 6-month program documentation, and approval processes. www.aetna.com

2. California DHCS Medi-Cal Announcement (December 2025) – Official state notice that Medi-Cal will discontinue coverage for Wegovy, Saxenda, and Zepbound for weight loss effective January 1, 2026. www.cmadocs.org

3. KFF Issue Brief – Medicaid Coverage of GLP-1s (November 2024) – Comprehensive research report showing that only 13 states cover obesity GLP-1 medications as of 2024, with all requiring prior authorization and strict BMI criteria. www.kff.org

4. GoodRx Press Release (November 17, 2025) – Official announcement of partnership with Novo Nordisk offering $199/month introductory pricing and $349/month ongoing for Ozempic and Wegovy. www.businesswire.com

5. Pennsylvania Health Law Project (2024) – Consumer advocacy resource describing Pennsylvania Medicaid coverage criteria for Wegovy, including BMI requirements and the requirement for diabetic patients to try diabetes GLP-1s first. www.phlp.org

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499